Staff Profile

Introduction

I am a viral immunologist that has migrated into the area of complement biology.

Roles and responsibilities

I am responsible for general lab management and safety.  

Supervision of undergraduates and masters students within the lab.

Facilitating use of the CBC within and without the group

Qualifications

June 2006 Doctor of Philosophy (Viral imunology) University of Birmingham.

June 1999 BSc (Hons) 2:1 Biochemistry University of Liverpool.

Previous Positions

March 2014 - current Research associate at Newcastle University

Multiple projects involving complement and treatment of auto-immune conditions.

Oct 2006-Jan 2010  E grade technician at Newcastle university.

Working on multiple projects including tissue culture, protein work, cloning and in vivo

Jan 2004-Oct 2006 Post doctoral researcher Cardiff university.

Investigating the interaction between NK calls and B cells in the productive lytic cycle.

• Schmidt CQ, Harder M, Nichols E, Hebecker M, Anliker M, Höchsmann B, Simmet T, Csincsi ÁI, Uzonyi B, Pappworth IY, Ricklin D, Lambris JD, Schrezenmeier H, Józsi M, Marchbank KJ. Selectivity of C3-opsonin targeted complement inhibitors: a distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients . Immunobiology 2016, 221(4), 503-511.
• Nichols E, Barbour TD, Pappworth IY, Wong EKS, Palmer J, Sheerin N, Pickering MC, Marchbank KJ. An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy. Kidney International 2015, 88(6), 1314-1322.
• Watson R, Wearmouth E, McLoughlin A-C, Jackson A, Ward S, Bertram P, Bennaceur K, Barker CE, Pappworth IY, Kavanagh D, Lea SM, Atkinson JP, Goodship THJ, Marchbank KJ. Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS). Molecular Immunology 2015, 63(2), 287-296.
• Nichols EM, Barbour TD, Kerr H, Pappworth IY, Wong EKS, Palmer J, Sheerin NS, Herbert A, Barlow PN, Pickering MC, Marchbank KJ. FH1-5^(18-20) ameliorates experimental C3 glomerulopathy; generation and testing of a murine version for further pre-clinical experiments. In: 15th European Meeting on Complement in Human Disease 2015. 2015, Uppsala, Sweden: Elsevier.
• Wong EKS, Marchbank K, Pappworth I, Walters R, Lomax-Browne H, Harris C, Morgan P, Pickering M, Goodship THJ, Malcomson R, Cook T, Johnson S, MPGN C3G Rare Dis Grp. The national study of membranoproliferative glomerulonephrtis and C3 glomerulopathy - characterisation of the paediatric cohort. In: 52nd ERA-EDTA Congress. 2015, London, UK: Oxford University Press.
• Ward S, Watson R, McLoughlin AC, Wearmouth E, Bertram P, Jackson A, Barker C, Pappworth IY, Kavanagh D, Lea SM, Morgan BP, Atkinson J, Goodship THJ, Marchbank KJ. Autoantibodies to CD59, CD55, CD46 and CD35 are not associated with aHUS. In: XXV International Complement Workshop. 2014, Rio de Janeiro, Brazil: Pergamon Press.
• Goodship THJ, Pappworth IY, Toth T, Denton M, Houlberg K, McCormick F, Warland D, Moore I, Hunze EM, Staniforth SJ, Hayes C, Cavalcante DP, Kavanagh D, Strain L, Herbert AP, Schmidt CQ, Barlow PN, Harris CL, Marchbank KJ. Factor H autoantibodies in membranoproliferative glomerulonephritis. Molecular Immunology 2012, 52(3-4), 200-206.
• Kavanagh D, Pappworth IY, Anderson H, Hayes CM, Moore I, Hunze EM, Bennaceur K, Roversi P, Lea S, Strain L, Ward R, Plant N, Nailescu C, Goodship TH, Marchbank KJ. Factor I Autoantibodies in Patients with Atypical Hemolytic Uremic Syndrome: Disease-Associated or an Epiphenomenon?. Clinical Journal of the American Society of Nephrology 2012, 7(3), 417-426.
• Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship THJ, Marchbank KJ. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010, 115(2), 379-387.
• Dhillon B, Wright AF, Tufail A, Pappworth I, Hayward C, Moore I, Strain L, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Armbrecht AM, Laude A, Deary IJ, Staniforth SJ, Holmes LV, Goodship THJ, Marchbank KJ. Complement Factor H Autoantibodies and Age-Related Macular Degeneration. Investigative Ophthalmology & Visual Science 2010, 51(11), 5858-5863.
• Pappworth IY, Denton M, Kavanagh D, Moore I, Strain L, Barlow PN, Herbert AP, Schmidt CQ. Factor H autoantibodies are associated with MPGN. In: Molecular Immunology: 23rd International National Complement Workshop. 2010, New York, USA: Pergamon.
• Kavanagh D, Pappworth IY, Roversi P, Tapson JS, Moore I, Strain L, Lea S, Goodship THJ, Marchbank KJ. Factor I autoantibodies are associated with atypical haemolytic uraemic syndrome. In: Molecular Immunology: 23rd International National Complement Workshop. 2010, New York, USA: Pergamon.
• Waters AM, Pappworth I, Marchbank K, Bockenhauer D, Tullus K, Pickering MC, Strain L, Sebire N, Shroff R, Marks SD, Goodship THJ, Rees L. Successful Renal Transplantation in Factor H Autoantibody Associated HUS with CFHR1 and 3 Deficiency and CFH Variant G2850T. American Journal of Transplantation 2010, 10(1), 168-172.
• Pappworth IY, Cruickshank MN, Hayes C, Knight AM, Ulgiati D, Marchbank KJ. The role of complement in the formation of B regulatory cells. In: Immunology: Annual Congress of the British Society for Immunology. 2010, Liverpool, UK: Wiley-Blackwell Publishing, Inc.
• Twohig JP, Pappworth IY, Sivasankar B, Kulik L, Bull M, Holers VM, Wang EC, Marchbank KJ. Defective B cell ontogeny and humoral immune response in mice prematurely expressing human complement receptor 2 (CR2, CD21) is similar to that seen in aging wild type mice. Molecular Immunology 2009, 46(10), 2002-2013.
• Pappworth IY, Kulik L, Haluszczak C, Reuter JW, Holers VM, Marchbank KJ. Increased B cell deletion and significantly reduced auto-antibody titre due to premature expression of human complement receptor 2 (CR2, CD21). Molecular Immunology 2009, 46(6), 1042-1049.
• Pappworth IY, Marchbank KJ. Normal B cell ontogeny in mice expressing human complement receptor type 1 under the control of a lambda light chain promoter enhancer. In: 11th European Meeting on Complement in Human Disease. 2007, Cardiff, Wales: Molecular Immunology, Pergamon.